Moxifloxacin Ophthalmic Solution USP, 0.5% has an estimated market size of $68mn for twelve months ending December 2018, according to IQVIA.
Alembic has a cumulative total of 86 ANDA approvals (73 final approvals and 13 tentative approvals) from USFDA, the filing added.
Moxifloxacin Ophthalmic Solution USP, 0.5% is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of certain organisms.
Alembic Pharmaceuticals Ltd is currently trading at Rs537 up by Rs1.85 or 0.35% from its previous closing of Rs535.15 on the BSE. The scrip opened at Rs536.65 and has touched a high and low of Rs541.10 and Rs536.65 respectively.